Newsroom

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), un’azienda biotecnologica globale che dà impulso alla ricerca e sviluppo di farmaci innovativi basati su anticorpi impiegando tecnologie all’avanguardia, oggi ha annunciato una collaborazione strategica con Moonlight Bio, Inc., società biotecnologica con sede a Seattle, pioniera nelle terapie cellulari all’avanguardia. Questa collaborazione mira a sviluppare terapie cellulari all’ava...

CHARLOTTE, N.C.--(BUSINESS WIRE)--Giles Foodservice Equipment is reducing its reliance on delivered liquid nitrogen by generating it on-site, a move projected to save the company $500,000 over the next decade. Powered by an ELGi air compressor and implemented with Mobile Mechanical Services, the new system supports continuous-duty manufacturing and future growth. Using compressed air, the system separates nitrogen from ambient air and delivers it directly to Giles’ laser cutting operations. By...

WOODSTOCK, Ga.--(BUSINESS WIRE)--Prestige Medical Group, a physician-led healthcare organization serving North Georgia for more than 20 years, announced plans to open a new medical office in Woodstock, Georgia. The new location, opened on March 24, 2026, located at 102 Springfield Center Drive, Woodstock, GA 30188. The Woodstock office represents a strategic expansion of Prestige Medical Group’s footprint, designed to improve access and convenience for patients and families in Cherokee County a...

NEW YORK--(BUSINESS WIRE)--KBRA releases research that explores the potential credit implications of the conflict involving Iran for the airline sector, including both near-term effects and the potential impact of a prolonged disruption. The conflict represents a multichannel shock for airlines, impairing flows through the Strait of Hormuz, disrupting regional refining activity, increasing shipping and insurance costs, and constraining Middle East airspace. The most immediate credit transmissio...

LIESTAL, Svizzera--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, “Curatis”) annuncia ricavi aziendali pari a 10,8 milioni di franchi (+57%) per il 2025. Curatis AG ha riportato un aumento organico del fatturato nella sua attività di distribuzione pari al 13%, da 9,5 milioni di franchi a 10,8 milioni di franchi. Il risultato netto è migliorato da una perdita di 4,3 milioni di franchi nel 2024 a una perdita di 1,4 milioni di franchi nel 2025. Ulteriori importanti dichiarazioni Nel settembre 2025...

LIESTAL, Zwitserland--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, “Curatis”) rapporteert een bedrijfsomzet van CHF 10,8m (+57%) voor 2025. Curatis AG kende een organische stijging van de verkoop in haar distributieactiviteiten met 13%, van CHF 9,5m naar CHF 10,8m. Het nettoresultaat verbeterde van een verlies van CHF 4,3m in 2024 naar een verlies van CHF 1,4m in 2025. Andere belangrijke verklaringen In september 2025 werd ons ontwikkelingsplan voor corticorelin gevalideerd tijdens een vergad...

LAS VEGAS--(BUSINESS WIRE)--Roseman Bioventures aims to accelerate the commercialization of life science innovations and expand the Nevada biotech ecosystem....

SAN JOSE, Calif.--(BUSINESS WIRE)--Altera and Arm Collaborate to Deliver Efficient, Programmable Solutions for AI Data Centers...

SAN JOSE, Calif.--(BUSINESS WIRE)--Today, Calix, Inc. (NYSE: CALX) recognized the recent achievements of Operation IFAST to rally the telecommunications industry around helping to stop human trafficking. The growing industry program equips communications service provider (CSP) field technicians with training to recognize and report signs of human trafficking during routine service visits. Operation IFAST helps CSPs collaborate with nonprofit partners and local law enforcement to help protect th...

LIESTAL, Suiza--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, «Curatis») obtiene unos ingresos de 10,8 millones de francos suizos (+57 %) para 2025. Curatis AG incrementó las ventas de su negocio de distribución de forma orgánica en un 13 %, de los 9,5 millones de CHF a 10,8 millones de CHF. El resultado neto mejoró, pasando de una pérdida de 4,3 millones de CHF en 2024 a una pérdida de 1,4 millones de CHF en 2025. Otras afirmaciones clave En septiembre de 2025, la FDA validó nuestro plan de d...